Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HbA1c \> or = to 7.5% and \< or = to 10.0%~* Body mass index (BMI) \< or = to 45 kg/m2~* Non smoker for at least 6 months before Screening~* Clinical diagnosis of type 2 diabetes mellitus for more than 12 months~* Currently receiving as diabetes treatment only metformin or 2 or more OADs and on stable doses for at least 3 months before enrollment~  * Subjects receiving metformin must be on at least 1.5gm daily, or up to the maximum tolerated dose~ * Subjects treated with a sulfonylurea must be on at least 50% of the total maximum approved dose for a given agent~ * Subjects receiving a DPP-4 inhibitor must receive the maximum approved dose specific for that agent~ * Metiglinide and alpha-glucoside inhibitors must be taken at the highest tolerated dose within the approved dose range~* No previous or current treatment with insulin, except during an acute illness, gestational diabetes, or at time of initial diagnosis of diabetes~* Forced expiratory volume in one second (FEV1) \> or = to 70% Third National Health and Nutrition Examination Survey (NHANES III) predicted~* Forced vital capacity (FVC) \> or = to 70% NHANES III predicted~* Forced expiratory volume in one second as a percentage of forced vital capacity (FEV1/FVC) \> or = to NHANES III lower limit of normal (LLN)~Exclusion Criteria:~* History of chronic obstructive pulmonary disease (COPD), clinically proven asthma, or any other clinically important pulmonary disease (eg, pulmonary fibrosis)~* Any clinically significant radiological findings on screening chest x-ray~* Use of medications for asthma, COPD, or any other chronic respiratory conditions~* Evidence of serious complications of diabetes (proliferative retinopathy, autonomic neuropathy with symptoms of gastroparesis or cardiac arrhythmia; sensory neuropathy that makes manipulation of the Gen2C inhaler difficult)~* Renal disease or renal dysfunction~* Significant cardiovascular dysfunction or history thereof within 12 months of screening; serious arrhythmia, treatment with medications to control/treat arrhythmias; myocardial infarction; cardiac surgery; history of valvular heart disease~* Previous or current use of amiodarone~* Treatment with glucagon-like peptide-1 (GLP-1) analogs, thiazolidinediones (TZD), or weight loss drugs (eg, sibutramine, orlistat) within 3 months of screening~* History of pulmonary embolism or deep venous thrombosis in the 12 months before Screening~* History of recent blood transfusion (within previous 3 months) or diagnosis of hemoglobinopathies that may affect HbA1c measurements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TI inhalation powder (Type: EXPERIMENTAL): Technosphere® Insulin powder administered via the Gen2 inhaler added to 2 or more stable OADs
- Technosphere powder (Type: PLACEBO_COMPARATOR): Technosphere powder (with no insulin) administered via the Gen2 inhaler added to 2 or more stable OADs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete